GlassScriptPhysician profile
Estefania Steiner
NPI 1558935775
$741.00
in general payments reported to CMS, 2019-2025
12 companies · $19.61 in 2025
The $19.61 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $319 · 2023: $335 · 2024: $67.77 · 2025: $19.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $165.14 | 2023-2024 | Cimzia, Bimzelx, Briviact |
| E.R. Squibb & Sons, L.L.C. | $99.87 | 2022 | |
| Csl Behring | $90.19 | 2022 | |
| Sarepta Therapeutics, INC. | $88.95 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $84.51 | 2022 | |
| Abbvie INC. | $66.25 | 2023-2025 | Botox |
| Sk Life Science, INC. | $43.40 | 2023 | Xcopri |
| Avanir Pharmaceuticals, INC. | $27.60 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.05 | 2024 | |
| Genentech USA, INC. | $19.93 | 2024 | Ocrevus |
| Pfizer INC. | $17.58 | 2023 | |
| Biogen, INC. | $16.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Estefania Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.